PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

• Maria Victoria Mateos Manteca,
• Sebastian Grosicki,
• Kihyun Kim,
• Eric Negre,
• Erik Vandendries

Affiliations

Maria Victoria Mateos Manteca

1 Salamanca University Hospital, Salamanca, Spain

Sebastian Grosicki

2 Medical University of Silesia, Katowice, Poland

Kihyun Kim

3 Sungkyunkwan University, School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South

Eric Negre

4 Pfizer, Inc., Paris, France

Erik Vandendries

5 Pfizer, Inc., Cambridge, United States